S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning

Mersana Therapeutics (MRSN) Earnings Date, Estimates & Call Transcripts

$3.81
+0.09 (+2.42%)
(As of 04/12/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 28)
-$0.16
Consensus EPS
(Feb. 28)
-$0.16
Skip Charts & View Estimated and Actual Earnings Data

MRSN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRSN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Mersana Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.21)($0.13)($0.17)
Q2 20242($0.22)($0.13)($0.18)
Q3 20242($0.22)($0.11)($0.17)
Q4 20242($0.22)($0.10)($0.16)
FY 20248($0.87)($0.47)($0.67)
Q1 20251($0.23)($0.23)($0.23)
Q2 20251($0.19)($0.19)($0.19)
Q3 20251($0.17)($0.17)($0.17)
Q4 20251($0.17)($0.17)($0.17)
FY 20254($0.76)($0.76)($0.76)

MRSN Earnings Date and Information

Mersana Therapeutics last posted its earnings data on February 28th, 2024. The reported ($0.16) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.16). The company earned $10.70 million during the quarter, compared to analyst estimates of $22.59 million. Its revenue was down 27.1% compared to the same quarter last year. Mersana Therapeutics has generated ($1.50) earnings per share over the last year (($1.50) diluted earnings per share). Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.67) per share. Mersana Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Mersana Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
2/28/2024Q4 2023($0.16)($0.16)-($0.16)$22.59 million$10.70 million    
11/7/2023Q3 2023($0.31)($0.35)($0.04)($0.35)$9.30 million$7.70 million    
8/8/2023Q2 2023($0.44)($0.47)($0.03)($0.47)$12.93 million$10.70 million
5/9/2023Q1 2023($0.41)($0.52)($0.11)($0.52)$18.29 million$7.80 million    
2/28/2023Q4 2022($0.47)($0.44)+$0.03($0.44)$27.85 million$14.69 million
11/7/2022Q3 2022($0.03)($0.61)($0.58)($0.61)$38.57 million$5.57 million
8/8/2022Q2 2022($0.50)($0.55)($0.05)($0.55)$3.18 million$4.28 million
5/9/2022Q1 2022($0.31)($0.59)($0.28)($0.59)$20.01 million$2.04 million    
2/28/2022Q4 2021($0.67)($0.68)($0.01)($0.68)$0.01 million$0.01 million    
11/9/2021Q3 2021($0.58)($0.63)($0.05)($0.63)$0.01 million$0.01 million    
8/6/2021Q2 2021($0.50)($0.59)($0.09)($0.59)-$0.01 million    
5/10/2021Q1 2021($0.39)($0.50)($0.11)($0.50)$0.25 million$0.01 million  

Mersana Therapeutics Earnings - Frequently Asked Questions

When is Mersana Therapeutics's earnings date?

Mersana Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on MRSN's earnings history.

Did Mersana Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Mersana Therapeutics (NASDAQ:MRSN) reported ($0.16) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.16). Learn more on analysts' earnings estimate vs. MRSN's actual earnings.

How can I listen to Mersana Therapeutics's earnings conference call?

The conference call for Mersana Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Mersana Therapeutics's conference call transcript?

The conference call transcript for Mersana Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Mersana Therapeutics generate each year?

Mersana Therapeutics (NASDAQ:MRSN) has a recorded annual revenue of $36.85 million.

How much profit does Mersana Therapeutics generate each year?

Mersana Therapeutics (NASDAQ:MRSN) has a recorded net income of -$171.67 million. MRSN has generated -$1.50 earnings per share over the last four quarters.

What is Mersana Therapeutics's EPS forecast for next year?

Mersana Therapeutics's earnings are expected to decrease from ($0.60) per share to ($0.67) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:MRSN) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners